Gastrointestinal is next for pumitamig
Bristol will advance the newest pivotal trials, in first-line colorectal and gastric cancers.
Tango waltzes towards phase 3
The company plans a pivotal pancreatic cancer trial after seeing two responses in eight patients.
Triple meeting 2025 – Revolution hints at post-KRAS promise
The G12C-selective elironrasib produces a 42% ORR in post-Lumakras/Krazati patients.
Grit enters the in vivo Car-T race
And Vironexis’s second gene therapy-encoded T-cell engager will soon go clinical.
Merck shoots for KRAS all comers
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
HengRui presses on in HER3, despite Merck’s failure
The Chinese group will soon start a pivotal trial of its ADC ruza-can in first-line NSCLC.
In triple-negative pumitamig concedes PD-L1-high disease
The Rosetta Breast-01 phase 3 trial will only evaluate patients with low PD-L1 expression.
